SEC Form 4 · accession 0001104659-18-065519
Rubius Therapeutics, Inc. · RUBY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pablo J Cagnoni
Officer — Chief Executive Officer · Director
Period of report
Oct 31, 2018
Accepted (ET)
Nov 1, 2018 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001709401
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.43 | Oct 31, 2018 | A | 164,400 | A | — | Oct 30, 2028 | Common Stock | 164,400 | 164,400 | D |
| Stock Option (Right to Buy)F2 | $16.43 | Oct 31, 2018 | A | 193,400 | A | — | Oct 30, 2028 | Common Stock | 193,400 | 193,400 | D |
Explanation of responses
- F1Upon the achievement of a performance milestone, 25% of this option shall vest effective as of October 31, 2019, then in 12 equal quarterly installments thereafter.
- F2Upon the achievement of a performance milestone, 50% of this option shall vest upon the achievement of a second performance milestone and 50% of this option shall vest upon the achievement of a third performance milestone.